Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Manufacturer

Cipla USA., Inc.

85 drugs, 164 product strengths, 24 recalls on record.

Drugs Cipla USA., Inc. makes

Atorvastatin+2.4%Generic · 50 makersPharmacies pay from$0.699 open recallsAlbuterol+0.4%Generic · 42 makersPharmacies pay from$5.543 open recallsAmlodipine-2.6%Generic · 33 makersPharmacies pay from$0.3017 open recallsSertraline+0.8%Generic · 42 makersPharmacies pay from$0.852 open recallsGabapentin+4.5%Generic · 72 makersPharmacies pay from$0.667 open recallsBupropion-0.4%Generic · 62 makersPharmacies pay from$2.113 open recallsEscitalopram-0.9%Generic · 38 makersPharmacies pay from$1.17Pantoprazole+2.7%Generic · 62 makersPharmacies pay from$1.103 open recallsPregabalin+5.4%Generic · 38 makersPharmacies pay from$1.341 open recallDapagliflozin+0.3%Generic · 18 makersPharmacies pay from$4.89Esomeprazole-3.4%Generic · 107 makersPharmacies pay from$3.844 open recallsCelecoxib-1.7%Generic · 51 makersPharmacies pay from$1.852 open recallsOseltamivir+0.2%Generic · 32 makersPharmacies pay from$9.33Liraglutide-6.7%Generic · 11 makersPharmacies pay from$257Limited availability1 open recallTadalafil+12.9%Generic · 39 makersPharmacies pay from$3.23Being discontinued6 open recallsMetoprolol+1.0%Generic · 65 makersPharmacies pay from$0.48Being discontinued9 open recallsMeloxicamNo changeGeneric · 36 makersPharmacies pay from$0.501 open recallCitalopram+2.3%Generic · 30 makersPharmacies pay from$0.86Cyclobenzaprine+0.6%Generic · 54 makersPharmacies pay from$0.521 open recallPravastatin-2.4%Generic · 27 makersPharmacies pay from$1.706 open recallsDiclofenac-1.0%Generic · 150 makersPharmacies pay from$1.89Being discontinued4 open recallsTopiramate+1.5%Generic · 36 makersPharmacies pay from$0.82Diltiazem+1.6%Generic · 34 makersPharmacies pay from$1.52Being discontinued9 open recallsFenofibrate-10.4%Generic · 42 makersPharmacies pay from$2.192 open recallsHydrocortisone-0.5%Generic · 212 makersPharmacies pay from$1.45Being discontinued5 open recallsSumatriptan+3.4%Generic · 39 makersPharmacies pay from$7.60Budesonide+4.1%Generic · 33 makersPharmacies pay from$15.543 open recallsTerbinafine+0.4%Generic · 42 makersPharmacies pay from$4.29Testosterone-3.4%Generic · 29 makersPharmacies pay from$35.2068 open recallsAlendronate+0.3%Generic · 12 makersPharmacies pay from$3.521 open recallRaloxifene-1.3%Generic · 16 makersPharmacies pay from$6.62Emtricitabine / tenofovir disoproxil-0.5%Generic · 23 makersPharmacies pay from$15.79Sevelamer-0.2%Generic · 36 makersPharmacies pay from$6.411 open recallMetaxalone+3.5%Generic · 35 makersPharmacies pay from$14.05Amoxicillin / clavulanate-0.7%Generic · 31 makersPharmacies pay from$6.241 open recallVitamin K1+5.4%Generic · 32 makersPharmacies pay from$279Gemfibrozil-0.3%Generic · 26 makersPharmacies pay from$3.10Being discontinuedHydrochlorothiazide / lisinopril-0.8%Generic · 24 makersPharmacies pay from$0.88Benztropine-1.9%Generic · 22 makersPharmacies pay from$1.91Being discontinuedNabumetone+5.0%Generic · 22 makersPharmacies pay from$4.04Calcium acetate+3.5%Generic · 20 makersPharmacies pay from$5.27Trospium-2.2%Generic · 20 makersPharmacies pay from$6.201 open recallPirfenidone-4.8%Generic · 19 makersPharmacies pay from$19.58Zonisamide-1.1%Generic · 18 makersPharmacies pay from$2.06PaclitaxelGeneric · 19 makersNo weekly priceCyclosporine-0.1%Generic · 14 makersPharmacies pay from$9.934 open recallsOmeprazole / sodium bicarbonate-6.7%Generic · 16 makersPharmacies pay from$8.27Capecitabine-0.4%Generic · 16 makersPharmacies pay from$10.85Tenofovir disoproxil+0.6%Generic · 15 makersPharmacies pay from$8.87Arformoterol+1.2%Generic · 15 makersPharmacies pay from$38.43Albuterol / ipratropium-2.8%Generic · 14 makersPharmacies pay from$6.88Cinacalcet+1.8%Generic · 13 makersPharmacies pay from$12.5720 open recallsDimethyl fumarate-3.0%Generic · 14 makersPharmacies pay from$11.45Darunavir-8.6%Generic · 12 makersPharmacies pay from$33.59Prucalopride-0.9%Generic · 12 makersPharmacies pay from$18.46VigabatrinGeneric · 14 makersNo weekly priceBeing discontinuedNadolol+15.5%Generic · 12 makersPharmacies pay from$3.82Abacavir+1.2%Generic · 12 makersPharmacies pay from$16.57Entecavir+12.6%Generic · 11 makersPharmacies pay from$7.384 open recallsExemestane-15.7%Generic · 11 makersPharmacies pay from$18.91Griseofulvin-2.3%Generic · 10 makersPharmacies pay from$29.58PalonosetronGeneric · 12 makersNo weekly priceBeing discontinuedLeuprolideNo changeGeneric · 10 makersPharmacies pay from$198Being discontinuedVilazodone-2.1%Generic · 9 makersPharmacies pay from$20.73Difluprednate-6.3%Generic · 10 makersPharmacies pay from$45.37Alfuzosin-0.4%Generic · 10 makersPharmacies pay from$3.14Ambrisentan-9.8%Generic · 10 makersPharmacies pay from$217Dihydroergotamine-0.3%Generic · 10 makersPharmacies pay from$2351 open recallFosfomycin+0.6%Generic · 10 makersPharmacies pay from$26.372 open recallsSalmon calcitonin+3.1%Generic · 10 makersPharmacies pay from$49.99Cyclophosphamide+2.4%Generic · 9 makersPharmacies pay from$34.443 open recallsGlucagon-12.8%Generic · 8 makersPharmacies pay from$1341 open recallRitonavir+0.2%Generic · 7 makersPharmacies pay from$18.23Being discontinuedEfavirenz / emtricitabine / tenofovir disoproxil-1.5%Generic · 7 makersPharmacies pay from$33.23Fosinopril+0.4%Generic · 6 makersPharmacies pay from$4.64Darifenacin+11.5%Generic · 6 makersPharmacies pay from$14.46IcatibantGeneric · 7 makersNo weekly priceBeing discontinuedLanthanum carbonate-1.9%Generic · 6 makersPharmacies pay from$93.444 open recallsNintedanib-10.4%Generic · 6 makersPharmacies pay from$362Abacavir / lamivudine-3.5%Generic · 5 makersPharmacies pay from$42.94Efavirenz-6.8%Generic · 5 makersPharmacies pay from$35.68Emtricitabine-0.1%Generic · 2 makersPharmacies pay from$380Being discontinuedFosinopril / hydrochlorothiazide+3.5%Generic · 2 makersPharmacies pay from$17.59Meprobamate+0.5%Generic · 2 makersPharmacies pay from$137LenalidomideGeneric · 2 makersNo weekly price

Recalls

Class IIOngoingOct 14, 2026Fosfomycin Tromethamine Granules for Oral SolutionFailed Impurities/Degradation SpecificationsCipla USA, Inc. · D-0014-2027Class IIOngoingJul 8, 2026Cinacalcet Hydrochloride TabletscGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).Cipla USA, Inc. · D-0661-2026Class IIOngoingJul 8, 2026Cinacalcet Hydrochloride TabletscGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).Cipla USA, Inc. · D-0675-2026Class IIOngoingJul 8, 2026Cinacalcet Hydrochloride TabletscGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).Cipla USA, Inc. · D-0676-2026Class IIOngoingApr 22, 2026Cinacalcet Hydrochloride TabletsCGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limitCipla USA, Inc. · D-0449-2026Class IIOngoingApr 22, 2026Cinacalcet Hydrochloride TabletsCGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limitCipla USA, Inc. · D-0450-2026Class IIOngoingApr 22, 2026Cinacalcet Hydrochloride TabletsCGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limitCipla USA, Inc. · D-0451-2026Class IIOngoingApr 15, 2026Lanreotide InjectionLack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.Cipla USA, Inc. · D-0422-2026Class IIOngoingApr 15, 2026Lanreotide InjectionLack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.Cipla USA, Inc. · D-0423-2026Class IIIOngoingMar 11, 2026Nilotinib CapsulesFailed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.Cipla USA, Inc. · D-0381-2026Class IIIOngoingMar 11, 2026Nilotinib CapsulesFailed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.Cipla USA, Inc. · D-0382-2026Class IIIOngoingJan 28, 2026Diclofenac Sodium Topical GelFailed PH SpecificationsCipla USA, Inc. · D-0291-2026Class IIOngoingJan 21, 2026Lanreotide InjectionPresence of Particulate Matter.Cipla USA, Inc. · D-0290-2026Class IIOngoingDec 17, 2025Lanthanum Carbonate chewable tabletsFailed stability specifications: Out of specification for hardness testCipla USA, Inc. · D-0217-2026Class IIOngoingDec 17, 2025Lanthanum Carbonate chewable tabletsFailed stability specifications: Out of specification for hardness testCipla USA, Inc. · D-0218-2026Class IIOngoingDec 17, 2025Cinacalcet Hydrochloride TabletsCGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.Cipla USA, Inc. · D-0224-2026Class IIOngoingDec 17, 2025Cinacalcet Hydrochloride TabletsCGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.Cipla USA, Inc. · D-0225-2026Class IIOngoingDec 17, 2025Cinacalcet Hydrochloride TabletsCGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.Cipla USA, Inc. · D-0226-2026Class IIIOngoingAug 27, 2025Albuterol SulfateFailed Stability Specifications: Out of specification results was observed in Induction Port during the analysis of Particle size distribution at the 12-month time point.Cipla USA, Inc. · D-0593-2025Class IIOngoingJul 30, 2025Budesonide Inhalation SuspensionLack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.Cipla USA, Inc. · D-0541-2025Class IIOngoingNov 20, 2024Lanthanum Carbonate Chewable TabletsFailed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets.Cipla USA, Inc. · D-0043-2025Class IIOngoingNov 20, 2024Lanthanum Carbonate Chewable TabletsFailed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets.Cipla USA, Inc. · D-0044-2025Class IITerminatedMay 1, 2024Ipratropium Bromide and Albuterol Sulfate Inhalation Solution USPShort fill: Complaints received of less fill volume in respule and few drops of liquid observed in the intact pouch.Cipla USA, Inc. · D-0471-2024Class ITerminatedJul 19, 2023Albuterol Sulfate Inhalation AerosolDefective container: empty inhaler and leakage observed through the inhaler valve due to partially missing bottom seat (gasket).Cipla USA, Inc. · D-0938-2023

About Cipla USA., Inc.

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.